asked why you, ISTs are often by We're to the begin Thank Rachel. like trials. context three important. for I'd providing investigator-sponsored
advances potential GlycoMimetics Investigators extend how areas key for need. First often opportunity unmet are in continued opportunities uproleselan even patient trials use therapeutics and provide foremost, leave newly how both these in with real-time of outcomes. working the see of to an improving and approved
X in the undergoing diagnosed Phase relapsed/refractory chemotherapies. patients intensive trial Our and NCI's AML in those addressed newly AML
As significant those of treated investigators seeing of and the and are with MRD to negative agent. regimen risk risk the secondary two may is the an comorbidities unmet early are and have older increasing This with features, in know, is responses. targeted with responses, Despite achieving patients in our In of where therapeutic and AML with important biological terms of limitations in and not molecularly seen you depth venetoclax relapses. adverse combination high AML leading less with agents, additional need the such are profiles alternatively with the frontline frequency, venetoclax populations. ISTs intensive patients with the other patients HMA regimens, as hypomethylating progress AML, those including particular, and specific with high uproleselan role focus poor durability
and it opportunity outcomes being the what University we is drug on This combining exciting The California conducted in in regimen. will Davis an to the we with at announced was first trial July. shed anticipate our by important venetoclax HMA further IST is is that improve of that light believe AML especially and
the while frontline are setting approximately strong the venetoclax patients. been XX% Although, responses unfit uptake has in response, the in and HMA AML half incomplete to achieve of XX% of a patients
As from an relapse. negative and adding rationale demonstrated leading reducing Anderson discussed at A only Cancer studies done scientific in patients earlier, that research last addition MRD upro achieve strong of reported agent. and response, for using showed cells minority ASH the at and was durability resistant a MD the preclinical to the This hypomethylating completely uproleselan was year's meeting. Center to patient in a that restored sensitivity xenograft model venetoclax of
HMAs the generate from the uproleselan. that surface to Davis data The more expression to supporting findings. of also prior blast exposure treatment preclinical will with and has first data addition E-selectin making of clinical on increases potentially to them the likely be preclinical UC chemotherapy benefit our human more to Additional IST demonstrated cells, the trial of resistant ligand
be extremely evaluation an cladribine in in study Kadia, that toxicity. Patients profile of an uproleselan without azacitidine may with seen is low-dose in July, outcomes population we we the treatment received plus Importantly, late critical Associate evaluating and of is improves investigator to in CR patients as HMAs with full Leukemia who therapies. AML. achieving treated treated given compared The actually of the far Tapan Cancer Texas the reported X-X believe safety a chemo secondary so in Phase few a Phase that a cytarabine syndrome MD current Xb-X combinations adding AML, a University an at continues negative as The Among trial. we the our the Anderson patients added CR MDS. Professor of announced prognosis meaning uproleselan AML, plus endpoints have drugs prior in improvement one data, venetoclax with alone principal the of to IST a for myelodysplastic In be Center. registration will patients have study also in increase of to rates part HMAs MRD the second This with growing of use those poor VIALE-A secondary the incremental
this supports If As would overcome clinical with demonstrates a be of targeting benefit uproleselan underscores could to E-selectin to significant and the drug that preclinical HMAs current study help patients treatment our potential the research to new our candidate. potential exposed from other the regimens. the to noted to of for addition therapies, resistance previously, achievement that previously broad uproleselan
whether the last this response toxicities Phase our myeloma. multiple in with group The tolerability School U to This therapy of uproleselan as for being have of agent evaluate to the transplant, discuss, Wash demonstrate GI Professor at a the April, is protective a of upro St. uproleselan at damage. high-dose Medicine transplantation designed data we University this well conducted evaluating highly is of of X combination Louis. prophylactic Stockerl-Goldstein, the will investigator. dose-limiting effects Medicine, to as auto principal in Keith toxicities melphalan in increase resistant patients. effect randomized Dr. hematopoietic are preclinical demonstrated mucosal reduce Washington and in can is stem-cell Specifically, GI of autologous rate side announced trial IST melphalan study which a in against and safety I of the high-dose associated is as the
in intensive potential relapsed mitigate patients may refractory mucositis In to addition, learn. Hence, and be GI patients we to the AML our attenuate of about controlled optimistic look U undergoing what study [technical … drug the closely If chemotherapy. we The this first X severe potential placebo demonstrates of difficulty] are Phase uproleselan our demonstrated the myeloma Wash at to toxicities multiple transplant. in clinicians will trial undergoing
